Abstract
Asthma is the most common chronic illness of the child, a frequent cause of hospitalization and morbidity in pediatrics. Symptomatology control is the therapeutic target, and the practitioner has to adapt the treatment recommendations to each case, with its own clinical and evolutionary particularities. Omalizumab is a humanized anti-human immunoglobulin E (human IgG) recombinant monoclonal antibody used in the treatment of asthma in children over 12 years of age. The authors exemplify the benefit of omalizumab in the management of asthma by presenting a clinical case.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
